Trials / Completed
CompletedNCT04481139
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Ankylosing Spondylitis
A Multicenter, Randomized, Double-blind, Placebo-controlled Adaptive Seamless Phase 2/3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Active Ankylosing Spondylitis Subjects
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 504 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with active ankylosing spondylitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR0302 | SHR0302, oral, once daily |
| DRUG | SHR0302 placebo | SHR0302 placebo, oral, once daily |
Timeline
- Start date
- 2020-10-14
- Primary completion
- 2022-11-15
- Completion
- 2023-05-12
- First posted
- 2020-07-22
- Last updated
- 2023-07-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04481139. Inclusion in this directory is not an endorsement.